Recent advances predict a bright future for nebulizers

Author:

Troy Michael1,Van Vleet Joseph2,Tashkin Donald1,Barjaktarevic Igor1

Affiliation:

1. Division of Pulmonary and Critical Care Medicine

2. UBreathe, Respiratory Therapy Department, University of California Los Angeles, Los Angeles, California, USA

Abstract

Purpose of review With the improvement in device technology and delivery methods of inhaled medications, along with development of novel compounds and recognition of the importance of personalized approach in the management of chronic airway diseases, nebulizers have not only maintained their place in the treatment hierarchy of airway disease but have also proven a vital platform for the development of new classes of drugs. Recent findings This short review explores recent advances in nebulized drug delivery in chronic obstructive pulmonary disease and other chronic airway diseases, emphasizing the progress in nebulizer technology, physiologic advantages of nebulized drug delivery and the high versatility of currently available and developing nebulizer-delivered pharmacotherapies. Summary Versatility and efficiency of nebulizers allows for a broad spectrum of existing and novel therapies to be clinically studied, facilitating the progress in phenotype-targeted pharmacotherapies in the management of chronic airway diseases

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pulmonary and Respiratory Medicine

Reference70 articles.

1. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society Clinical Practice Guideline;Nici;Am J Respir Crit Care Med,2020

2. 100 years of drug delivery to the lungs;Lavorini;Handb Exp Pharmacol,2019

3. History of aerosol therapy: liquid nebulization to MDIs to DPIs;Anderson;Respir Care,2005

4. Rethinking the paradigm for the development of inhaled drugs;Pritchard;Int J Pharm,2015

5. New inhaler devices: the good, the bad and the ugly;Lavorini;Respiration,2014

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Reply to Gan et al., to Calzetta et al., and to Poor;American Journal of Respiratory and Critical Care Medicine;2024-01-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3